Claims:

1. A cell therapeutic composition, comprising:

a therapeutically effective amount of at least one of CD56+ and/or CD3−/CD56+ NK cells, wherein purity of the NK cells in the cell therapeutic composition is at least 90% relative to other cells in the cell therapeutic composition;

IL-2 at a concentration of 50-50,000 IU/mL; and

a pharmaceutically acceptable carrier,

wherein the cell therapeutic composition is in a form suitable for administration to a human patient in need of NK cell therapy.

2. The composition of claim 1, wherein the therapeutically effective amount is 1×10^{6} to 1×10^{11} NK cells per kg of body weight of the human patient.

3. The composition of claim 2, wherein the composition is at about 4 degrees centigrade.

4. The cell therapeutic composition of claim 1, wherein IL-2 is present at 50-1,000 IU/mL.

5. The cell therapeutic composition of claim 4, wherein the cell therapeutic composition does not comprise IL-21.

6. The cell therapeutic composition of claim 5, wherein the cell therapeutic composition is between 2 and 8° C.

7. The cell therapeutic composition of claim 6, wherein the cell therapeutic composition is at about 4 degrees centigrade.

8. The cell therapeutic composition of claim 1, wherein IL-2 is present at about 500 IU/mL.

9. A bag containing a cell composition, the composition comprising:

1×10^{6} to 1×10^{11} NK cells per kg of body weight of a human subject, wherein the NK cells are CD56+ and/or CD3−/CD56+ cells derived from peripheral blood mononuclear cells (PBMCs), wherein the NK cells are at least about 90% pure, wherein less than about 1% of cells in the bag are T cells;

IL-2 at a concentration of 50-50,000 IU/mL; and

a pharmaceutically acceptable carrier comprising Hartmann's solution, albumin, DMSO and no IL-21.

10. A cell composition, comprising:

at least one of CD56+ and/or CD3−/CD56+ NK cells, wherein purity of the NK cells in the cell composition is at least 90% relative to other cells in the cell composition;

IL-2 at a concentration of 50-50,000 IU/mL;

a pharmaceutically acceptable carrier comprising:

DMSO, and

no IL-21,

wherein the cell composition is in a form suitable for administration to a human patient.

11. The cell composition of claim 10, wherein IL-2 is present at 50-1,000 IU/mL.

12. The cell composition of claim 11, further comprising Hartmann's solution.

13. The cell composition of claim 12, further comprising albumin.

14. The cell composition of claim 13, wherein the albumin is present at 1%.

15. The cell therapeutic composition of claim 13, wherein IL-2 is present at about 500 IU/mL.

16. The cell composition of claim 13, wherein the cell composition is between 2 and 8° C.

17. The composition of claim 13, wherein the composition is at about 4 degrees centigrade.

18. A cell composition, comprising:

at least one of CD56+ and/or CD3−/CD56+ NK cells, wherein purity of the NK cells in the cell composition is at least 90% relative to other cells in the cell composition;

IL-2 at a concentration of 500-50,000 IU/mL;

a pharmaceutically acceptable carrier,

wherein the cell composition is in a form suitable for administration to a human patient.

19. The cell composition of claim 18, wherein the cells have been stored for at least 24 hours.

20. The cell composition of claim 18, wherein the cells have been stored for at least 48 hours.